Byrne Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Byrne Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-98	Closed	-$8K	–	541
2021 Q4	$8K	Buy	+98	New	+$9.02K	0.01%	411

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Byrne Asset Management's NBIX Position: Q1 2022 in Review

Byrne Asset Management sold out of Neurocrine Biosciences (NBIX) in Q1 2022, closing a stake of 98 shares — an estimated $8K sold.

Byrne Asset Management first reported a position in NBIX in Q4 2021 and held it in 1 quarter. The position peaked at $8K in Q4 2021. 426 funds tracked by Wall St. Rank hold NBIX as of Q1 2022.

Byrne Asset Management reported no remaining Neurocrine Biosciences position as of Q1 2022 after selling out during the quarter.
Byrne Asset Management sold 98 Neurocrine Biosciences shares in Q1 2022, an estimated $8K.
Byrne Asset Management first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 1 quarter.
Byrne Asset Management's Neurocrine Biosciences position peaked at $8K in Q4 2021.
426 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2022.

Based on Byrne Asset Management's 13F filing for Q1 2022, filed 5 Apr 2022.